BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33616477)

  • 1. Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas.
    Yeagley M; Chobrutskiy BI; Gozlan EC; Medikonda N; Patel DN; Falasiri S; Callahan BM; Huda T; Blanck G
    Pediatr Hematol Oncol; 2021 Apr; 38(3):251-264. PubMed ID: 33616477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma.
    Hudock TR; Barker VR; Manley BJ; Chobrutskiy A; Chobrutskiy BI; Diaz MJ; Song JJ; Blanck G
    Cancer Biomark; 2023; 38(1):103-110. PubMed ID: 37545223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates.
    Chobrutskiy BI; Yeagley M; Diviney A; Zaman S; Gozlan EC; Tipping P; Koohestani DM; Roca AM; Blanck G
    Immunology; 2020 Apr; 159(4):373-383. PubMed ID: 31821535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delineation of a T-cell receptor CDR3-cancer mutanome aromaticity factor, assessable via blood samples, that facilitates the establishment of survival distinctions in bladder cancer.
    Waweru JW; Mwangi KW; Barker VR; Gozlan EC; Yeagley M; Blanck G; Makokha FW
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4359-4366. PubMed ID: 36098856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer.
    Chobrutskiy BI; Chobrutskiy A; Zaman S; Yeagley M; Huda TI; Blanck G
    Mol Immunol; 2021 Jul; 135():247-253. PubMed ID: 33933816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis.
    Zaman S; Chobrutskiy BI; Patel JS; Diviney A; Tu YN; Tong WL; Gill T; Blanck G
    Viral Immunol; 2020 Jun; 33(5):404-412. PubMed ID: 32315578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members.
    Diaz MJ; Chobrutskiy BI; Zaman S; Blanck G
    Cancer Treat Res Commun; 2020; 24():100196. PubMed ID: 32769037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates.
    Hsiang M; Chobrutskiy BI; Diaz M; Huda TI; Creadore S; Zaman S; Cios KJ; Gozlan EC; Blanck G
    Transl Oncol; 2021 Jun; 14(6):101069. PubMed ID: 33780706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities.
    Agnila DRL; Huda TI; Eakins RA; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
    Melanoma Res; 2023 Aug; 33(4):275-282. PubMed ID: 37222076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma.
    Chobrutskiy BI; Yeagley M; Tipping P; Zaman S; Diviney A; Patel DN; Falasiri S; Uversky VN; Blanck G
    Oncogene; 2020 Feb; 39(8):1773-1783. PubMed ID: 31740784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGL CDR3 Hydropathy and Antigen Chemical Complementarity Associated with Greater Disease-Free Survival in Lung Adenocarcinoma: Implications for Gender Disparities.
    Charkowick SV; Huda TI; Patel DN; Yeagley M; Arturo JF; Cios KJ; Gozlan EC; Chobrutskiy A; Chobrutskiy BI; Blanck G
    Biochem Genet; 2024 Feb; 62(1):530-546. PubMed ID: 37392243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer.
    Chobrutskiy BI; Zaman S; Diviney A; Mihyu MM; Blanck G
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):615-623. PubMed ID: 30539280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrostatic complementarity of B-cell receptor CDR3s and TP53-mutant amino acids in breast cancer is associated with increased disease-free survival rates.
    Arturo JF; Chobrutskiy BI; Yeagley M; Patel DN; Falasiri S; Patel JS; Blanck G
    Cell Mol Immunol; 2020 Jul; 17(7):776-778. PubMed ID: 31729463
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor resident, TRA anti-viral CDR3 chemical sequence motifs are associated with a better breast cancer outcome.
    Diaz MJ; Kacsoh DB; Patel DN; Yeagley M; Hsiang M; Blanck G
    Genes Immun; 2023 Apr; 24(2):92-98. PubMed ID: 36805542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenomics Parameters for Patient Stratification in Alzheimer's Disease.
    Huda TI; Diaz MJ; Gozlan EC; Chobrutskiy A; Chobrutskiy BI; Blanck G
    J Alzheimers Dis; 2022; 88(2):619-629. PubMed ID: 35662120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity.
    Eakins RA; Chobrutskiy A; Teer JK; Patel DN; Hsiang M; Huda TI; Zaman S; Sexton WJ; Coppola D; Falasiri S; Blanck G; Chobrutskiy BI
    Mol Immunol; 2022 Oct; 150():58-66. PubMed ID: 35987136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune DNA signature of T-cell infiltration in breast tumor exomes.
    Levy E; Marty R; Gárate Calderón V; Woo B; Dow M; Armisen R; Carter H; Harismendy O
    Sci Rep; 2016 Jul; 6():30064. PubMed ID: 27452728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical Complementarity of Tumor Resident, Adaptive Immune Receptor CDR3s and Previously Defined Hepatitis C Virus Epitopes Correlates with Improved Outcomes in Hepatocellular Carcinoma.
    Song JJ; Chobrutskiy A; Chobrutskiy BI; Cios KJ; Huda TI; Eakins RA; Diaz MJ; Blanck G
    Viral Immunol; 2023 Dec; 36(10):669-677. PubMed ID: 38052065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCR CDR3-antigen chemical complementarity associated with poor ovarian cancer outcomes: A vestigial immune response to early cancer antigens?
    Barker VR; Varkhedi M; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
    Am J Reprod Immunol; 2023 Jan; 89(1):e13639. PubMed ID: 36317868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrostatic Complementarities of Glioblastoma-Resident T-Cell Receptors and Cancer Testis Antigens Linked to Poor Outcomes and High Levels of Sphingosine Kinase-2 Expression.
    Arias MA; Cios KJ; Kacsoh DB; Montgomery BE; Song JJ; Patel AR; Chobrutskiy A; Chobrutskiy BI; Blanck G
    Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.